Advertisement

Pharmacy World and Science

, Volume 27, Issue 5, pp 399–402 | Cite as

When Do Children Convert from Liquid Antiretroviral to Solid Formulations?

  • Vincent W. Yeung
  • Ian C. K. WongEmail author
Research Article

Abstract

Background: Liquid formulations are usually regarded as the gold standard in paediatric formulation; but sometimes, liquid formulations have stability and taste problems as well as being inconvenient for travelling. Therefore, for the management of long-term illness, some older children, parents and clinicians would prefer to use solid formulations. However, there is a lack of studies to investigate the age at which children are converted from liquid to solid formulations.

Objectives: (1) To investigate the age range at which children convert from liquid antiretroviral drug formulations to solid formulations, the formulations are abacavir, didanosine, lamivudine, stavudine, and zidovudine. (2) To calculate how long children stay on each of five UK liquid formulations (retention time) and factors affecting the retention times of the above liquid formulations.

Method: This was a retrospective medical records survey at Great Ormond Street Hospital for Children, London, United Kingdom. Patients’ treatment details were entered into SPSS for Windows v. 11.0 and the retention times for the above liquid formulations were calculated i.e., from initiation of the liquid treatment to conversion to solid preparation. The retention times of different preparations were then compared using Cox regression analysis.

Results: A total of 92 patients are included in the analysis. The overall average age at conversion was 7.3 years (95% CI 6.3–8.2). Patients on stavudine were more likely to switch to the corresponding solid dose form than the other four medicines (P < 0.001); more than 50% of patients on stavudine switched to solid formulation after nine months of treatment, however, less than 25% of patients on other formulations switched during the same period.

Conclusion:Children taking antiretroviral liquid preparations change to solid dose forms at approximately seven years of age. However, for stavudine, children are more likely to take the solid form at an earlier age.

Keywords

Age of conversion Antiretroviral Formulation Long-term treatment Retention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schirm, E, Tobi, H, Vries, TW, Choonara, I, De Jong-van den Berg, LT 2003Lack of appropriate formulations of medicines for children in the communityActa Paediatr9214869PubMedGoogle Scholar
  2. 2.
    Num, AJ 2003Making medicines that children can takeArch Dis Child8836971Google Scholar
  3. 3.
    Conroy, S 2002Unlicensed and off-label drug use: issues and recommendationsPaediatr Drugs43539PubMedGoogle Scholar
  4. 4.
    Prescribing for children. Merec Bulletin 2000; 11: 5–8 (www.npc.co.uk/MeReC_Bulletins/2000Volumes/pdfs/vol11n02.pdf).Google Scholar
  5. 5.
    Dajani, AD 1996Adherence to physicians’ instructions as a factor in managing streptococcal phargngitisPediatrics9797681PubMedGoogle Scholar
  6. 6.
    Matsui, DM 1997Drug compliance in pediatrics: clinical and research issuesPediatr Clin North Am44114CrossRefPubMedGoogle Scholar
  7. 7.
    Blanchard, N, Primovic, J, Leff, RD 1999Compliance with pediatric medicationsJ Paediatr Pharm Prac41815Google Scholar
  8. 8.
    Fotheringham, MJ, Sawyer, MG 1995Adherence to recommended medical regimens in childhood and adolescenceJ Paediatr Child Health31728PubMedGoogle Scholar
  9. 9.
    Hazzard, A, Hitchinson, SJ, Krawiecki, N 1990Factors related to adherence to medication regimens in pediatric seizure patientsJ Pediatr Psychol155435PubMedGoogle Scholar
  10. 10.
    Sharma, PL, Nurpeisov, V, Hernandez-Santiago, B, Beltran, T, Schinazi, RF 2004Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptaseCurr Top Med Chem4895919CrossRefPubMedGoogle Scholar
  11. 11.
    Cox, DR 1972Regression models and life tablesJ R Stat Soc34187202Google Scholar
  12. 12.
    Wong, ICK, Mawer, GE, Sander, JWAS, Lhatoo, SD 2001A pharmacoepidemiological study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsyEpilepsia4213548CrossRefPubMedGoogle Scholar
  13. 13.
    Lhatoo, SD, Wong, ICK, Polizzi, G, Sander, JWAS 2000Long-term retention rates of lamotrigine, gabapentin and topiramate in chronic epilepsyEpilepsia4115926PubMedGoogle Scholar
  14. 14.
    Lhatoo, SD, Wong, ICK, Sander, JWAS 2000Prognostic factors for long-term retention of topiramateEpilepsia4133841CrossRefPubMedGoogle Scholar
  15. 15.
    Wong, ICK, Chadwick, D, Fenwick, PBC, Mawer, GE, Sander, JWAS 1999The long-term use of gabapentin, lamotrigine and vigabatrin in patients with chronic epilepsyEpilepsia40143945CrossRefPubMedGoogle Scholar
  16. 16.
    Dahlquist, LM, Blount, RL 1984Teaching a six-year-old girl to swallow pillsJ Behav Ther Exp Psychiatry151713PubMedGoogle Scholar
  17. 17.
    Babbitt, RL, Parrish, JM, Brierly, PE, Kohr, MA 1991Teaching developmentally disabled children with chronic illness to swallow prescribed capsulesJ Dev Behav Pediatr1222935PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  1. 1.Centre for Paediatric Pharmacy Research, The School of Pharmacy, The Institute of Child Health and Great Ormond Street Hospital for Children NHS TrustUniversity of LondonLondonUK

Personalised recommendations